Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-12-03T00:31:07.132Z Has data issue: false hasContentIssue false
  • English
  • Français

The Side-Effects of Fluphenazine Decanoate

Published online by Cambridge University Press:  29 January 2018

D. A. W. Johnson
D. A. W. Johnson*
Affiliation:
Crumpsall Hospital, Manchester, 8
Get access Rights & Permissions [Opens in a new window]

Extract

The unwanted effects of the phenothiazines can be divided into two categories; those effects which represent the pharmacodynamic actions of a particular drug and occur as a function of dosage and individual susceptibility; and the hyper-sensitivity reactions (Shepherd et al., 1968). This latter group of side-effects is relatively rare, and there is no suggestion in the literature that they occur more frequently with the injectable long-acting phenothiazines (LAP) than with the oral forms. With the first available long-acting phenothiazine (fluphenazine enanthate) motor side-effects were frequently observed, particularly during the first few days after injection (Millar and Daniel, 1967; Lowther, 1969; Malm, 1970). Initial studies have suggested that fluphenazine decanoate is less likely to produce these unwanted extrapyramidal effects (Neal and Imlah, 1968; Ayd, 1970). So far, however, no study has attempted to make a quantitative evaluation of the problem of side-effects in the clinical situation of longterm medication. Since both the therapeutic efficacy and the unwanted extra-pyramidal side-effects are dose-dependent, it is meaningless to measure the incidence of side-effects without also recording the therapeutic gain: a low incidence of side-effects might only reflect a non-therapeutic dose of medication. Further, any such study should be continued for at least two months after the last reduction in dosage, as it is well recognized that loss of clinical control may be postponed for many weeks after phenothiazines have been discontinued.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 123 , Issue 576 , November 1973 , pp. 519 - 522
Copyright
Copyright © Royal College of Psychiatrists, 1973 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alarcon, R. de, and Carney, M. W. P. (1969). ‘Severe depressive mood changes following slow-release intramuscular fluphenazine injections.’ British Medical Journal, iii, 564–567 CrossRefGoogle Scholar
Ayd, F. J. (1961). ‘A survey of drug-induced extrapyramidal reactions.’ Journal of the American Medical Association, 175, 1054–1060.Google Scholar
Ayd, F. J. (1966). International Drug Therapy Newsletter, 1, 6.Google Scholar
Ayd, F. J. (1970). International Drug Therapy Newsletter, 5, 13.Google Scholar
Beck, A. T. (1967). Depression: Clinical, Experimental and Theoretical Aspects. New York: Hoeber Medical Division.Google Scholar
British Medical Journal (1971). Editorial— ‘Long acting phenothiazines in schizophrenia’, i, 189–190.Google Scholar
Denham, J. (1961). ‘The implications of extrapyrimidal symptoms in the treatment of schizophrenia.’ Revue Canadienne de Biologie, 20, 545–548.Google Scholar
Denham, J. and Adamson, L. (1971). ‘The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.’ Acta Psychiatrica Scandinavica, 47, 420–430.Google Scholar
Heather, R., and Johnson, D. A. W. (1973). ‘The clinical use of the Beck Depressive Inventory.’ Awaiting publication.Google Scholar
Johnson, D. A. W. (1971). ‘The dangers of fluphenazine.’ Brit. J. Psychiat., 118, 376–377.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. and Freeman, H. L. (1972). ‘The long-acting tranquillizers.’ The Practitioner, 208, 395–400.Google Scholar
Johnson, D. A. W. and Freeman, H. L. (1973). ‘Drug defaulting by patients on longacting phenothiazines’ Psychological Medicine. 3 115–119.Google Scholar
Kennedy, H. L., Hershon, H. I., and McGuire, R. J. (1971). ‘Extrapyramidal disorders after prolonged phenothiazine therapy.’ British Journal of Psychiatry, 118, 509–518.Google Scholar
Lowther, J. (1969). ‘The effect of fluphenazine enanthate on chronic and relapsing schiphrenia.’ British Journal of Psychiatry, 115, 691–692.CrossRefGoogle Scholar
Malm, U. (1970). ‘Intramuscular long-acting fluphenazine in the treatment of schizophrenia.’ Acta Psychiatrica Scandinavica, 46, 225–237.Google Scholar
Millar, J., and Daniel, G. R. (1967). ‘A trial of fluphenazine enanthate in chronic schizophrenia.’ British Journal of Psychiatry, 113, 1431–1432.Google Scholar
Neal, C. D., and Imlah, N. W. (1968). ‘Fluphenazine decanoate: a second long-acting phenothiazine.’ British Journal of Social Psychiatry, 2, 178–186.Google Scholar
Shepherd, M., Lader, M., and Rodnioht, R. (1968). Clinical Psychopharmacology. London: English Universities Press Ltd.Google Scholar
Simpson, G. M., Amuse, D., Blair, J. R., and Farkas, T. (1964). ‘Phenothiazine-produced extra-pyramidal system disturbance.’ Archives of General Psychiatry, 10, 199–208.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.